ORX142

About Centessa Pharmaceuticals

Centessa Pharmaceuticals, founded in 2020, consolidates specialized biotech assets under a unified, capital-efficient corporate structure with a patient-centric mission. Its primary achievement is advancing a pipeline of oral OX2R agonists, led by ORX750, which is in Phase 2 studies for narcolepsy and idiopathic hypersomnia, targeting a fundamental biological pathway for wakefulness. The company's strategy employs focused, data-driven development teams for each asset to rapidly progress programs, supported by a leadership team with deep industry and scientific expertise. A significant recent development is the announced acquisition by Eli Lilly, validating the platform's potential.

Therapeutic Areas